MedStar Authors catalog › Details for: Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).
Citation: American Journal of Cardiology. 110(8):1119-24, 2012 Oct 15..Journal: The American journal of cardiology.ISSN: 0002-9149.Full author list: Waksman R; Ghali M; Goodroe R; Ryan T; Turco M; Ring M; McGarry T; Dobies D; Shammas N; Steinberg DH; Swymelar S; Kaneshige K; Torguson R.UI/PMID: 22762711.Subject(s): Aged | Coronary Angiography | *Coronary Artery Disease/th [Therapy] | *Drug-Eluting Stents | Female | Follow-Up Studies | Humans | *Immunosuppressive Agents/ad [Administration & Dosage] | Male | Middle Aged | *Paclitaxel/ad [Administration & Dosage] | Sirolimus/ad [Administration & Dosage] | *Sirolimus/aa [Analogs & Derivatives] | Treatment Outcome | *Tubulin Modulators/ad [Administration & Dosage] | United StatesInstitution(s): MedStar Health Research Institute | MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal Article | Multicenter Study | Research Support, Non-U.S. Gov'tOnline resources: Click here to access onlineDigital Object Identifier: http://dx.doi.org/10.1016/j.amjcard.2012.05.050 (Click here)Abbreviated citation: Am J Cardiol. 110(8):1119-24, 2012 Oct 15.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006.Abstract: Registry Experience at the Washington Hospital Center, DES - Taxus Liberte Versus Xience V (REWARDS TLX) is a physician-initiated, retrospective, real-world, multicenter, observational study for all patients >18 years of age subjected to percutaneous coronary intervention with everolimus-eluting stents (EESs) or paclitaxel-eluting stents (PESs). Outcomes of patients receiving a TAXUS Liberte or XIENCE V drug-eluting stent were compared. Baseline clinical, procedural, and follow-up data at 12 months were collected from 10 clinical centers by an electronic data capture system. The study's primary end point was major adverse cardiac events: a composite of all-cause death, Q-wave myocardial infarction, target vessel revascularization, and stent thrombosis. The trial is registered with http://www.clinicaltrials.gov (NCT01134159). Data were entered for 1,195 patients (PES, n = 595; EES, n = 600). Baseline clinical characteristics were similar except for higher dyslipidemia, systemic hypertension, and family history of coronary artery disease in the EES group. In-hospital outcome was similar between groups, with an overall in-hospital stent thrombosis rate of 0.2%. The primary end point at 12 months was similar (EES 7.8% vs 10.8%, p = 0.082). Overall stent thrombosis rate was lower in the EES group (0.3% vs 1.2%, respectively, p = 0.107); however, target lesion revascularization was similar (PES, hazard ratio 1.46, 95% confidence interval 0.98 to 2.19, p = 0.064). There was no difference in overall mortality between groups. In conclusion, second-generation EESs and PESs demonstrated similar efficacy and safety profiles for broadened patient and lesion subsets compared to a selected population from the pivotal trials. However, for composite efficacy and safety end points, EESs outperformed second-generation PESs. Copyright 2012 Elsevier Inc. All rights reserved.